Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics

Journal of Medicinal Chemistry

Volumn 45, Issue 8, 2002, Pages 1607-1623

  Dragovich, Peter S ^a   Prins, Thomas J ^a   Zhou, Ru ^a   Brown, Edward L ^a   Maldonado, Fausto C ^a   Fuhrman, Shella A ^a   Zalman, Leora S ^a   Tuntland, Tove ^a   Lee, Caroline A ^a   Patick, Amy K ^a   Matthews, David A ^a   Hendrickson, Thomas F ^a,b   Kosa, Maha B ^a   Liu, Bo ^a   Batugo, Minerva R ^a   Gleeson, Jean Paul R ^a   Sakata, Sylvie K ^a   Chen, Lijian ^a   Guzman, Mark C ^a   Meador III, James W ^a   Ferre, Rose Ann ^a   Worland, Stephen T ^a,c   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b SCHRÖDINGER INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRIDONE DERIVATIVE; 4 [3' (3'',4'' DIFLUOROPHENYL) 2' [3''' [[1'''' (5'''' METHYLISOXAZOL 3'''' YL)METHANOYL]AMINO] 2''' OXO 2'''H PYRIDIN 1''' YL]PROPANOYLAMINO] 5 (2''''' OXOPYRROLIDIN 3''''' YL)PENT 2 ENOIC ACID ISOPROPYL ESTE; ANTIVIRUS AGENT; CYSTEINE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN RHINOVIRUS; HUMAN TISSUE; MASS SPECTROMETRY; NONHUMAN; SEROTYPE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; DOGS; DRUG STABILITY; HUMANS; LIGANDS; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR MIMICRY; PEPTIDES; PROTEASE INHIBITORS; PROTEIN BINDING; PYRIDONES; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL PROTEINS;

EID: 0037061621     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010469k     Document Type: Article

References (87)

1. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids
2. Rhinoviruses
3. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment
4. Rhinovirus colds
5. The common cold
6. Rhinoviruses
7. Picornaviridae: The viruses and their replication
8. Viral proteinases
9. A collaborative report: Rhinoviruses-extension of the numbering system from 89 to 100
10. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection
11. Rhinoviruses and their ICAM receptors
12. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14
13. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism
14. Pleconaril, a broad spectrum antipicornaviral agent
15. Short synthesis and anti-rhinoviral activity of imidazo[1,2-a]pyridines: The effect of Acyl groups at 3-position
16. Picornavirus inhibitors
17. Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro
18. Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli
19. Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli
20. Proteolytic enzymes of the viruses of the family picornaviridae
21. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein
22. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases
23. Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: Structural and functional implications
24. Poliovirus-encoded proteinase 3C: A possible evolutionary link between cellular serine and cysteine proteinase families
25. Complete sequence of the RNA genome of human rhinovirus 16, a clinically useful common cold virus belonging to the ICAM-1 receptor group
26. Biologically, active protease 3C of human rhinovirus 1A is expressed from a cloned cDNA segmant in Escherichia coli
27. The nucleotide sequence of human rhinovirus 1B: Molecular relationships within the rhinovirus genus
28. Evolutionary relationships within the human rhinovirus genus: Comparison of serotypes 89, 2, and 14
29. Molecular cloning and sequence determination of the genomic regions encoding protease and genome-linked protein of three picornaviruses
30. Human rhinovirus 2: Complete nucleotide sequence and proteolytic processing signals in the capsid protein region
31. Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14
32. The complete nucleotide sequence of a common cold virus: Human rhinovirus 14
33. Recent advances in the development of human rhinovirus 3C protease inhibitors
34. Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections
35. Human rhinovirus 3C protease inhibitors: Recent developments
36. On the size of the active site in proteases. I. Papain
37. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies
38. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication
39. Vinyl sulfonate esters and vinyl sulfonamides: Potent, irreversible inhibitors of cysteine proteases
40. Crystal structure of human cathepsin K complexed with a potent inhibitor
41. Peptidyl vinyl sulphones: A new class of potent and selective cysteine protease inhibitors
42. Vinyl sulfones as mechanism-based cysteine protease inhibitors
43. Structure-activity relationships for inhibition of papain by peptide Michael acceptors
44. Vinylogous amino acid esters: A new class of inactivators for thiol proteases
45. 1 lactam moieties as L-glutamine replacements
46. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
47. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease
48. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses
49. Current research on respiratory viral infections: Third international symposium
50. Antiviral therapy for enteroviruses and rhinoviruses
51. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics
52. L-373,890, an achiral, noncovalent, subnanomolar thrombin inhibitor
53. Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates
54. Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors
55. Structure-based design of non-peptidic pyridone aldehydes as inhibitors of interleukin-1β converting enzyme
56. Pyridone-based peptidomimetic inhibitors of interleukin-1β-converting enzyme (ICE)
57. The influence of peptide structure on transport across Caco-2 cells
58. The influence of peptide structure on transport across Caco-2 cells II. Peptide bond modification which results in improved permeability
59. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies
60. Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. 1. Optimization of tripeptides incorporating N-terminal amides
61. Structure based drug design
62. Molecular recognition of protein-ligand complexes: Applications to drug design
63. The art and practice of structure-based drug design: A molecular modeling perspective
64. Application of the three-dimensional structures of protein target molecules in structure-based drug design
65. Non-peptidic inhibitors of human leukocyte elastase. 1. The design and synthesis of pyridone-containing inhibitors
66. Synthesis and nucleophilic substitutions of 3-Alkyl-5-chloroisoxazoles
67. Enantioselective preparation of α-acyloxy ketones from α-hydroxy and α-amino acids
68. A new amidoalkynylation using alkynlyzinc reagent
69. A convenient synthesis of 4-unsubstituted β-lactams
70. An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester
71. Reactions of Wittig reagents with episulfides or elemental sulfur
72. A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin Periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species
73. DENZO in data collection and processing
74. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: Design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements
75. In vitro activity of Pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity